<DOC>
	<DOCNO>NCT01395810</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , Japan , North America South Africa . The aim evaluate safety efficacy nonacog beta pegol ( NNC-0156-0000-0009 ) long-term exposure patient haemophilia B . This trial extension trial NN7999-3747 ( NCT01333111/paradigm™ 2 ) NN7999-3773 ( NCT01386528/paradigm™ 3 ) .</brief_summary>
	<brief_title>Safety Efficacy NNC-0156-0000-0009 After Long-Term Exposure Patients With Haemophilia B : An Extension Trials NN7999-3747 NN7999-3773</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Previous participation NN79993747 ( NCT01333111 ) and/or NN79993773 Known history FIX inhibitor base exist medical record , laboratory report review patient LAR ( legal acceptable representative ) interview Current FIX inhibitor equal 0.6 BU ( Bethesda Units ) Congenital acquire coagulation disorder haemophilia B Previous arterial thrombotic event ( e.g . myocardial infarction intracranial thrombosis ) previous deep venous thrombosis pulmonary embolism ( define available medical record ) Any disease ( liver , kidney , inflammatory mental disorder include ) condition , accord Investigator 's ( trial physician ) judgement , could imply potential hazard patient , interfere trial participation , interfere trial outcome</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>